At 35, Mr. Sreejith presented with advanced-stage hair loss primarily affecting the vertex (crown) and mid-scalp regions. Despite his younger age, the progression had reached a point where the scalp was highly visible with minimal terminal hair density remaining. The objective was to utilize the D Lapp Non-Surgical Protocol to intercept further loss and aggressively stimulate new growth.
2. Therapeutic Intervention
The patient underwent a high-concentration regenerative cycle designed to optimize the scalp environment:
Exosome Therapy: Utilized to deliver extracellular vesicles that carry microRNA and proteins to dormant follicles, signaling them to re-enter the growth phase.
Stem Cell Activation: A bio-targeted approach to increase the population of progenitor cells within the hair bulb.
Transepidermal Drug Distribution (TEDD): Ensures the therapeutic compounds reach the dermal papilla layer without the trauma or downtime associated with traditional micro-needling or injections.
Photobiomodulation (PBM): Application of therapeutic light to reduce oxidative stress in the scalp and fuel cellular metabolism.
3. Progressive Outcomes (90-Day Observation)
Phase
Clinical Observations
Visual Impact
Day 1
Baseline: Significant "bald spot" on the crown; hair quality in the surrounding areas is thin and brittle.
High scalp exposure.
Day 45
Early Sprouting: Emerging vellus hairs visible under magnification. The texture of the scalp begins to change from smooth to slightly "fuzzy."
Softening of the bald patch.
Day 90
Terminal Growth: Significant filling of the vertex. New hair shows improved pigmentation and thickness, successfully blending with the existing hair.
Full, natural-looking coverage.
4. Clinical Summary
Mr. Sreejith’s results are particularly notable due to his age; by intervening at 35 with advanced regenerative technology, the clinic was able to restore a youthful hairline and crown density that typically would have required thousands of grafts in a surgical transplant. The D Lapp protocol continues to prove that biological activation is a highly effective alternative for Grade 6-7 patients.